Q4

ADM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Archer-Daniels-Midland Company Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Wednesday, February 28, 2024
Court, Person, News, Growth, Complaint, Q4, ADM, FY, ADM (company), Defendant

As ADM was aggressively acquiring companies to expand its capabilities in Nutrition, investors were under the impression that the segment was growing rapidly.

Key Points: 
  • As ADM was aggressively acquiring companies to expand its capabilities in Nutrition, investors were under the impression that the segment was growing rapidly.
  • As alleged, Defendants’ accounting practices for the segment misrepresented its true financial results and prospects, including its operating profits (“OP”).
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioNTech, Mobileye, BioVie, and ADM and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, February 27, 2024
Complaint, Pfizer–BioNTech COVID-19 vaccine, BioNTech, Pfizer, OSI, FDA, News, Food, Mobileye, Growth, GCP, Risk, Q4, COVID-19, Good clinical practice, BNTX, EyeQ, ADM, Patient, Clinical trial, FY, Hand, Defendant, P.C

According to the filed complaint, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects.

Key Points: 
  • According to the filed complaint, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects.
  • As ADM was aggressively acquiring companies to expand its capabilities in Nutrition, investors were under the impression that the segment was growing rapidly.
  • As a result, ADM delayed its Q4 and FY 2023 earnings release and withdrew its outlook for the Nutrition segment.
  • For more information on the ADM class action go to: https://bespc.com/cases/ADM

ARCHER-DANIELS-MIDLAND COMPANY (NYSE: ADM) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Archer-Daniels-Midland Company

Retrieved on: 
Monday, February 26, 2024
Court, Nutrition, News, Advertising, Growth, Sale, Complaint, District court, Q4, ADM, FY, ADM (company), Security (finance)

NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:

Key Points: 
  • NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:
    Do you, or did you, own shares of Archer-Daniels-Midland Company (NYSE: ADM)?
  • Throughout the Class Period, Defendants made misleading statements about the Nutrition segment as a future profit-driver for the Company.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Archer Daniels Midland (ADM) Faces Securities Class Action After Placing CFO On Leave Amid Accounting Probe and SEC Investigation – Hagens Berman

Retrieved on: 
Friday, February 23, 2024
Archery, SAN, Person, Nutrition, News, Growth, Risk, Q4, ADM, FY, Pharmaceutical industry

SAN FRANCISCO, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Archer Daniels Midland Co. (NYSE: ADM) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Archer Daniels Midland Co. (NYSE: ADM) investors who suffered substantial losses to submit your losses now .
  • Archer Daniels Midland Co. (ADM) Securities Fraud Class Action:
    The litigation focuses on Archer Daniels’ statements about the performance of its Nutrition segment, a business the company poured billions of dollars into to protect against commodity price volatility in its legacy agricultural commodities trading business.
  • Investors began to learn the truth on Jan. 21, 2024, when Archer Daniels announced that it had placed CFO Vikram Luther on leave effective immediately.
  • This news sent the price of Archer Daniels shares crashing as much as $14.46 (or about 21%) lower during intraday trading on Jan. 22, 2024.

GrafTech International (EAF) Delivers Weak 2023 Financial Results Amid Securities Class Action - Hagens Berman

Retrieved on: 
Friday, February 23, 2024
GrafTech, SAN, Person, Disclosure, Q4, Mexican, Particulates, EAF

SAN FRANCISCO, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges GrafTech International Ltd. (NYSE: EAF) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges GrafTech International Ltd. (NYSE: EAF) investors who suffered substantial losses to submit your losses now .
  • On Feb. 14, 2024, GrafTech released its financial results for 2023, reporting a net loss of $255 million.
  • Timothy Flanagan, GrafTech’s interim CEO, cited the temporary suspension of operations in Mexico as one of the reasons why 2023 results fell short of expectations.
  • The disclosure comes on the heels of a securities class action complaint alleging GrafTech misrepresented and concealed that its Monterrey facility was not in compliance with applicable environmental laws and regulations.

ADM SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In ADM To Contact Him Directly To Discuss Their Options

Retrieved on: 
Friday, February 23, 2024
Court, News, Advertising, Growth, Q4, Woman, ADM, LLP, FY, ADM (company), Defendant

NEW YORK, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Archer-Daniels-Midland Company (“ADM” or the “Company”) (NYSE: ADM) and reminds investors of the March 25, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Key Points: 
  • Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • As ADM was aggressively acquiring companies to expand its capabilities in Nutrition, investors were under the impression that the segment was growing rapidly.
  • As a result, ADM delayed its Q4 and FY 2023 earnings release and withdrew its outlook for the Nutrition segment.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding ADM’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioNTech, Mobileye, BioVie, and ADM and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, February 23, 2024
Complaint, Pfizer–BioNTech COVID-19 vaccine, BioNTech, Pfizer, OSI, FDA, News, Food, Mobileye, Growth, GCP, Risk, Q4, COVID-19, Good clinical practice, BNTX, EyeQ, ADM, Patient, Clinical trial, FY, Hand, Defendant, P.C

According to the filed complaint, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects.

Key Points: 
  • According to the filed complaint, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects.
  • As ADM was aggressively acquiring companies to expand its capabilities in Nutrition, investors were under the impression that the segment was growing rapidly.
  • As a result, ADM delayed its Q4 and FY 2023 earnings release and withdrew its outlook for the Nutrition segment.
  • For more information on the ADM class action go to: https://bespc.com/cases/ADM

ADM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Archer-Daniels-Midland Company Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Wednesday, February 21, 2024
Court, Person, News, Growth, Complaint, Q4, ADM, FY, ADM (company), Defendant

As ADM was aggressively acquiring companies to expand its capabilities in Nutrition, investors were under the impression that the segment was growing rapidly.

Key Points: 
  • As ADM was aggressively acquiring companies to expand its capabilities in Nutrition, investors were under the impression that the segment was growing rapidly.
  • As alleged, Defendants’ accounting practices for the segment misrepresented its true financial results and prospects, including its operating profits (“OP”).
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Beyond, Inc. reports fourth quarter 2023 financial results, sees rapid growth in active customer file, delivering positive sales results since Nov. 1

Retrieved on: 
Tuesday, February 20, 2024
Bed Bath & Beyond, Acquisition, Total, PIN, Investment, Telephone, Growth, Civil Service (United Kingdom), Commerce, Q4, Beyond, Bed, Pharmaceutical industry

“Active customers returned to year-over-year growth for the first time in three years, with over 700,000 customers added to our customer file.

Key Points: 
  • “Active customers returned to year-over-year growth for the first time in three years, with over 700,000 customers added to our customer file.
  • Our mandate is to grow our customer file, provide a service level that improves retention and minimizes customer returns.
  • We believe that mandate will result in improved margins and profitability through Beyond.com and our core business.
  • Beyond will hold a conference call and webcast to discuss its fourth quarter and full year 2023 financial results on Wednesday, February 21, 2024 at 8:30 a.m.

QuidelOrtho (QDEL) Stock Crashes After Posting YoY Revenue Decline, Analyst Downgrades - Hagens Berman

Retrieved on: 
Tuesday, February 20, 2024
Q4, News, FY, Hagens Berman, JPMorgan Chase, QuidelOrtho, Person

“We’re investigating whether QuidelOrtho may have potentially misrepresented or concealed the true extent of the deterioration in its respiratory revenue,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

Key Points: 
  • “We’re investigating whether QuidelOrtho may have potentially misrepresented or concealed the true extent of the deterioration in its respiratory revenue,” said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • Analysts did not react kindly to the news, with JP Morgan reportedly downgrading the stock to underweight and slashing its price target, pointing to a lack of clarity over the company’s outlook.
  • This news sent the price of QuidelOrtho crashing $21.50, or over 32%, lower on Feb. 14, 2024.
  • Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.